SCHEMBL555032

SCHEMBL555032

COc1cccc(Oc2ccc(N)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 1.00
ALDH1A1 P00352 8/20 0.80
MEN1 O00255 3/20 0.80
KMT2A Q03164 3/20 0.80
MAPT P10636 2/20 0.80
MITF O75030 1/20 0.80
GAA P10253 1/20 0.80
GFER P55789 1/20 0.80
NLRP1 Q9C000 1/20 0.80
NOD2 Q9HC29 1/20 0.80
CYP3A4 P08684 3/20 0.61
KDM4E B2RXH2 1/20 0.60
BRCA1 P38398 1/20 0.60
HBB P68871 1/20 0.60
HSD17B10 Q99714 1/20 0.60
MAOA P21397 1/20 0.59
NPC1 O15118 1/20 0.58
RAB9A P51151 1/20 0.58
NLRP3 Q96P20 1/20 0.58
TDP1 Q9NUW8 4/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1980004 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
Acetic Acid SCHEMBL4630370 0.90 SMN1; SMN2 (0.81) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6290623 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL562469 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6289307 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL10709191 0.89 SMN1; SMN2 (0.80) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL4092959 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL6290330 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL22289568 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT
SCHEMBL1270594 0.89 ALDH1A1 (1.00) SMN1; SMN2ALDH1A1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3797991-B1 PREPREG AND PRODUCTION METHOD THEREFOR, SLIT TAPE PREPREG, CARBON FIBER-REINFORCED COMPOSITE MATERIAL TORAY INDUSTRIES (JP) 2025-10-29 EP disclosed
US-12448510-B2 Prepreg, method for producing same, and slit tape prepreg TORAY INDUSTRIES, INC. (JP) 2025-10-21 US disclosed
EP-3995536-B1 PREPREG AND FIBER-REINFORCED COMPOSITE MATERIAL TORAY INDUSTRIES (JP) 2025-06-18 EP disclosed
US-20250051335-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2025-02-13 US disclosed
US-20240166798-A1 EPOXY RESIN COMPOSITION, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL TORAY INDUSTRIES, INC. (JP) 2024-05-23 US disclosed
EP-4368182-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS Consejo Superior De Investigaciones Científicas - CSIC (ES) 2024-05-15 EP disclosed
EP-4314108-A1 EPOXY RESIN COMPOSITION, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL Toray Industries, Inc. (JP) 2024-02-07 EP disclosed
US-20230357561-A1 PREPREG, METHOD FOR PRODUCING SAME, AND SLIT TAPE PREPREG TORAY INDUSTRIES, INC. (JP) 2023-11-09 US disclosed
US-11708487-B2 Prepreg, method for producing same, and slit tape prepreg TORAY INDUSTRIES, INC. (JP) 2023-07-25 US disclosed
WO-2023281149-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2023-01-12 WO disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
US-8263216-B2 Epoxy resin composition for fiber-reinforced composite material, prepreg, and fiber-reinforced composite material TORAY INDUSTRIES, INC. (JP) 2012-09-11 US disclosed
US-20120035299-A1 EPOXY RESIN COMPOSITION FOR FIBER-REINFORCED COMPOSITE MATERIAL, PREPREG, AND FIBER-REINFORCED COMPOSITE MATERIAL TORAY INDUSTRIES, INC. (JP) 2012-02-09 US disclosed
EP-2341092-A1 EPOXY COMPOUND AND MANUFACTURING METHOD THEREOF Toray Fine Chemicals Co., Ltd. (JP) 2011-07-06 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed
US-20110040111-A1 EPOXY COMPOUND AND MANUFACTURING METHOD THEREOF TORAY FINE CHEMICALS CO., LTD. (JP) 2011-02-17 US disclosed
EP-0113922-A2 Process for the manufacture of cationic methine dyes BAYER AG (DE) 1984-07-25 EP disclosed
EP-0113921-A2 Process for the manufacture of stable solutions of cationic methine dyes BAYER AG (DE) 1984-07-25 EP disclosed
EP-0113920-A2 Process for the manufacture of stable solutions of cationic methine dyes, and their use in spin dyeing BAYER AG (DE) 1984-07-25 EP disclosed
US-4036955-A TREATMENT OF THROMBOSIS MITSUBISHI CHEMICAL INDUSTRIES LTD. (JA) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110040111-A1 EPOXY COMPOUND AND MANUFACTURING METHOD THEREOF CYP2E1, CYP4A11, CYP1A1 SMN1; SMN2 3389/4885ALDH1A1 576/4885MEN1 2577/4885
US-20250051335-A1 TAU-TUBULIN KINASE (TTBK) INHIBITOR COMPOUNDS TTBK1, TTBK2, MAPT SMN1; SMN2 180/4885ALDH1A1 3733/4885MEN1 4044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.